Roxithromycin dry suspension
Function and Efficacy
This product is a new generation of macrolide antibiotics, mainly acting on Gram-positive bacteria, anaerobic bacteria, chlamydia and mycoplasma. Its in vitro antibacterial effect is similar to that of erythromycin, and its activity against streptococci, Haemophilus ducreyi, Chlamydia trachomatis, Mycoplasma pneumoniae, oral or vaginal anaerobic bacteria is similar to that of erythromycin; its effect on Campylobacter, Bordetella pertussis and Haemophilus influenzae is not as good as that of erythromycin; it also has an inhibitory effect on Mycobacterium tuberculosis, most atypical mycobacteria, Campylobacter jejuni, Corynebacterium diphtheriae, and Pasteurella multocida; it has no antibacterial activity against G bacteria. Some bacteria have cross-resistance to erythromycin and this product, and this product is particularly effective against mycoplasma, chlamydia and Legionella infections. Its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.
Ingredients
The main ingredient of this product is: Roxithromycin. Its chemical name is: 9-{O-[(2-methoxyethoxy)-methyl]oxime}erythromycin. Molecular formula: C14H76N2O15 Molecular weight: 837.03
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| RoxithromycinIngredients |
A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobes, Chlamydia and Mycoplasma. Its activity against Streptococcus, Haemophilus ducreyi, Chlamydia trachomatis, Mycoplasma pneumoniae, oral or vaginal anaerobes is similar to that of erythromycin; it also has inhibitory effects on Mycobacterium tuberculosis, most atypical mycobacteria, Campylobacter jejuni, Corynebacterium diphtheriae, and Pasteurella multocida; it has no antibacterial activity against G bacteria. Its antibacterial effect in vivo is 1 to 4 times stronger than that of erythromycin, and it is particularly effective against mycoplasma, chlamydia and Legionella infections. More |
80214-83-1 | 28 |
Appearance
Dry suspension. This product is powder with aromatic odor and sweet taste.
Indication
1. Suitable for the following infections caused by sensitive strains: (1) Upper respiratory tract infection. (2) Lower respiratory tract infection. (3) Ear, nose and throat infection. (4) Genital infection (except gonococcal infection). (5) Skin and soft tissue infection. 2. Can also be used for mycoplasma pneumonia, Chlamydia trachomatis infection and Legionnaires' disease, etc.
Usage and Dosage
Oral administration: Pour the powder into an appropriate amount of warm water, shake well and take. 1 Adults: 150 mg once, twice a day, or as directed by a doctor. 2 Children: 2.5~5 mg/kg per body weight, twice a day, or as directed by a doctor. Recommended dosage for children: Children 6-11 kg, 25 mg each morning and evening. Children 12-23 kg, 50 mg each morning and evening. Children 24-40 kg, 75 mg each morning and evening.
Adverse Reactions
1. Gastrointestinal reactions may be seen: nausea, vomiting, loss of appetite, abdominal pain. 2. Abnormal liver function may be seen: elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). 3. Skin rash may be seen.
Precautions
It is contraindicated for those who are allergic to this product.
Special Population Medication
Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.
Drug Interactions
Not yet clear.
Storage
Sealed, store in a cool, dark and dry place.
Packaging Specification
25 mg (25,000 units)
Validity Period
24 months
Manufacturer
Shenyang YONGDA Pharaceutical Co., Ltd.
-
Founded in:
1995-06-14 -
Address:
No. 20, Canghai Road, Shenyang Economic and Technological Development Zone -
Tax NO.:
91210100604612702T -
Registered Funds:
26.05 million yuan -
Website:
-
Email: